SHILPA MEDICARE LTD
SHILPAMED · General/Diversified · NSE
₹414
Current Market Price
Fair Value (DCF)
₹218
Margin of Safety
-47.2%
Updated 2d ago
YieldIQ Score
57/100
Piotroski F-Score
7/9
Economic Moat
Narrow
Confidence
22%
ROE
—
Debt/Equity
0.24
WACC
11.1%
Market Cap
₹8,095 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
—
Return on capital employed
EV / EBITDA
22.2×
Enterprise multiple
Debt / EBITDA
1.6×
Leverage vs earnings
Interest Coverage
—
EBIT covers interest
Current Ratio
—
Short-term liquidity
Asset Turnover
0.39×
Revenue per ₹ of assets
Revenue CAGR (3Y)
4.1%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹413.9
Bear case
₹127.27
MoS -225.2%
Base case
₹218.42
MoS -89.5%
Bull case
₹276.44
MoS -49.7%
Ratio Trends
SHILPAMED · last 7 annual periods
ROE
3.3%
ROCE
10.5%
Operating Margin
—
Debt / Equity
0.25×
PE
128.4×
EV / EBITDA
40.9×
Historical Financials
SHILPAMED · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹830 Cr | ₹1146 Cr | ₹66.5 Cr | ₹292 Cr | ₹1285 Cr | +11.5% |
| EBITDA | — | ₹223 Cr | ₹113 Cr | ₹246 Cr | ₹311 Cr | +8.7% |
| EBIT | ₹273 Cr | ₹143 Cr | ₹-20.4 Cr | ₹52.1 Cr | — | -33.9% |
| PAT | ₹184 Cr | ₹60.7 Cr | ₹-28.9 Cr | ₹24.5 Cr | ₹78.3 Cr | -19.3% |
| EPS (diluted) | ₹22.62 | ₹7.26 | ₹-3.33 | ₹2.82 | — | -40.6% |
| CFO | ₹80.7 Cr | ₹105 Cr | ₹2.1 Cr | ₹135 Cr | ₹132 Cr | +13.1% |
| CapEx | — | — | — | — | ₹-244 Cr | — |
| FCF | — | — | — | — | ₹-111 Cr | — |
| Total Assets | — | ₹2875 Cr | ₹2517 Cr | ₹3093 Cr | ₹3311 Cr | +3.6% |
| Total Debt | — | — | ₹165 Cr | ₹375 Cr | ₹588 Cr | +37.5% |
| Shareholders' Equity | — | — | ₹2118 Cr | ₹1809 Cr | ₹2364 Cr | +2.8% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
SHILPAMED vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
| PGHL PGHL | — | — | Pending | 3.1% | — |
| AKUMS AKUMS | — | — | Pending | 11.0% | — |
| SUDEEPPHRM SUDEEPPHRM | — | — | Pending | 28.1% | — |
| VIYASH VIYASH | — | — | Pending | 2.8% | — |
| STAR STAR | — | — | Pending | 138.9% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for SHILPAMED in the last 10 years.
Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of SHILPAMED →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for SHILPAMED →
Compare
Head-to-head with peers
Compare SHILPAMED side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse SHILPAMEDNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.